Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹102 Cr
Revenue (TTM)
₹309 Cr
Net Profit (TTM)
₹8 Cr
ROE
9.7 %
ROCE
10.1 %
P/E Ratio
12.5
P/B Ratio
1.3
Industry P/E
26.59
EV/EBITDA
7.7
Div. Yield
1.9 %
Debt to Equity
1.9
Book Value
₹50.3
EPS
₹5.1
Face value
10
Shares outstanding
15,924,872
CFO
₹109.26 Cr
EBITDA
₹204.28 Cr
Net Profit
₹17.22 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Bal Pharma
| -10.8 | -13.1 | -10.4 | -27.2 | -0.8 | 3.4 | -4.6 |
|
BSE Healthcare
| -4.7 | -5.8 | -5.4 | 1.3 | 23.7 | 14.0 | 10.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Bal Pharma
| -41.7 | 22.0 | 9.8 | -13.9 | 88.3 | 33.5 | -47.9 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Bal Pharma
|
65.4 | 101.9 | 309.5 | 8.1 | 6.1 | 10.4 | 12.5 | 1.3 |
| 2,791.2 | 34,920.1 | 5,201.6 | 1,014.6 | 22.9 | 25 | 34.4 | 7.6 | |
| 7,827.5 | 19,544.3 | 2,177.5 | 200.9 | 11.3 | 26.5 | 97.3 | 23.5 | |
| 1,565.8 | 11,917.5 | 2,089.5 | 622.0 | 31.3 | 20.4 | 19.4 | 3.6 | |
| 1,332.1 | 18,429.0 | 3,078.2 | 469.4 | 26.4 | 14.9 | 42.7 | 5.1 | |
| 1,961.1 | 31,410.1 | 4,193.0 | 753.8 | 22.7 | 20.8 | 41.7 | 7.8 | |
| 4,887.1 | 22,333.8 | 2,482.3 | 853.6 | 33.7 | 18.9 | 26.2 | 5.6 | |
| 4,778.6 | 7,918.9 | 1,348.5 | 293.5 | 28.1 | 50.7 | 27 | 11.4 | |
| 388.9 | 7,603.2 | 1,432.0 | 149.0 | 19.1 | 7.9 | 50.7 | 3.1 | |
| 971.2 | 8,938.5 | 4,725.6 | 528.7 | 14.9 | 20.7 | 17.5 | 3.0 |
No Review & Analysis are available.
Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products,... intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic preparations targeting conditions, such as prostate enlargement, renal calculi, male infertility, and women health, etc. under the Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin brands; anti-hypertensive, anti-lipidemic, and anti-obese products; skin care and bone health products; and cardiac care products under the Secremet and Servace brands. In addition, the company offers a range of APIs for therapeutic areas, such as anti-histamine, platelet inhibitor, anti-diabetic, anti-convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, and acne treatment, etc.; and various formulations, including tablets, capsules, syrups, suspensions, ophthalmic, creams, and ointments. Further, it engages in the treatment of gastrointestinal disorders; and piles, fistula, and constipation. The company exports its products to approximately 30 countries. Bal Pharma Limited was incorporated in 1987 and is based in Bengaluru, India. Read more
Incorporated
1987
Chairman
--
Managing Director
Shailesh Siroya
Headquarters
Bengaluru, Karnataka
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Bal Pharma Ltd is ₹65.40 (NSE) and ₹64.01 (BSE) as of 02-Apr-2026 IST. Bal Pharma Ltd has given a return of -0.83% in the last 3 years.
The P/E ratio of Bal Pharma Ltd is 12.55 times as on 02-Apr-2026, a 53 discount to its peers’ median range of 26.59 times.
The P/B ratio of Bal Pharma Ltd is 1.27 times as on 02-Apr-2026, a 72 discount to its peers’ median range of 4.49 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
18.35
|
1.71
|
|
2024
|
19.51
|
2.00
|
|
2023
|
40.83
|
1.65
|
|
2022
|
28.49
|
2.77
|
|
2021
|
16.80
|
1.51
|
The 52-week high and low of Bal Pharma Ltd are Rs 128.74 and Rs 60.00 as of 04-Apr-2026.
Bal Pharma Ltd has a market capitalisation of ₹ 102 Cr as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Bal Pharma Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹0.53
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.